Home / Science / Health /  Moderna’s mRNA cancer vaccine shows promise in preliminary study

A customized Moderna Inc. vaccine combined with a Merck & Co. cancer drug helped ward off the recurrence of the skin cancer melanoma after surgery in patients in a mid-stage clinical trial, the companies said.

Recommended For You
Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout